Expanded Access to Derazantinib for Advanced Intrahepatic Cholangiocarcinoma with FGFR Genetic Changes
Sponsor: Basilea Pharmaceutica
ClinicalTrials ID:NCT04087876
This program offers access to the drug derazantinib for patients with advanced intrahepatic cholangiocarcinoma (iCCA) who have specific genetic changes and cannot undergo surgery. It is available to those who have no other treatment options and cannot join ongoing clinical trials.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Basilea is offering access to the drug derazantinib for patients with advanced intrahepatic cholangiocarcinoma (iCCA) that cannot be surgically removed and has specific genetic changes known as FGFR alterations. This access is provided on an individual basis while the drug is still being studied in clinical trials.
Eligibility Criteria
Inclusion Criteria
- All other treatment options have been tried without success.
- The patient cannot join any ongoing clinical trials or is too far away from trial locations, including those with derazantinib.
- There is a belief that the benefits of taking derazantinib outweigh the risks of using an investigational drug.
- The patient is willing and able to sign a consent form agreeing to the treatment.
- If needed, approval from the relevant health authorities is obtained.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.